Building For a Transformative Future
From our start in Beijing in 2010, with a handful of entrepreneurial scientists and developers…
…to today, with a global team across five continents, including over 1,000 in the United States and hundreds in Europe and Australia, driving a rich pipeline and high-value commercial medicines…
…we are united by a shared passion for discovering and developing potential new medicines and improving access to them.
And we’re just getting started.
2010
![2010](https://www.beigene.com.au/wp-content/uploads/2022/04/2010-300x300.jpg)
2010
Founded as a research and development company
2011
![2011](https://www.beigene.com.au/wp-content/uploads/2022/04/2011-scaled-1-300x200.jpg)
2011
Initiated discovery programs at our first R&D center, in Beijing
2012
![2012](https://www.beigene.com.au/wp-content/uploads/2022/04/2012-1-scaled-1-300x200.jpg)
2012
Initiated PD-1 and BTK discovery programs
2013
![2013](https://www.beigene.com.au/wp-content/uploads/2022/04/2013-scaled-1-300x200.jpg)
2013
Started first clinical development in Australia
2014
![2014](https://www.beigene.com.au/wp-content/uploads/2022/04/2014-scaled-1-300x200.jpg)
2014
Began clinical development of pamiparib and zanubrutinib
2015
![2015](https://www.beigene.com.au/wp-content/uploads/2022/04/2015.png)
2015
Opened first U.S. office (Massachusetts)
2016
![2016](https://www.beigene.com.au/wp-content/uploads/2022/04/2016-300x200.jpg)
2016
Completed Nasdaq IPO
2017
![2020](https://www.beigene.com.au/wp-content/uploads/2022/04/2020-scaled-1-300x200.jpg)
2017
Became a commercial-stage company in China with medicines in-licensed from Celgene (now part of BMS); initiated the first global Phase 3 registrational trial of zanubrutinib; completed construction of first manufacturing facility in Suzhou, China
2018
![2017](https://www.beigene.com.au/wp-content/uploads/2022/04/2017-300x200.jpg)
2018
Completed dual primary listing on the Hong Kong Stock Exchange; established presence in Europe; secured our first China national reimbursement
2019
![2018](https://www.beigene.com.au/wp-content/uploads/2022/04/2018-scaled-1-300x200.jpg)
2019
Received first global approval, in the U.S., for BRUKINSA® (zanubrutinib); received first global approval, in China, for tislelizumab; entered global strategic collaboration with Amgen; completed first biologics manufacturing plant in Guangzhou, China
2020
![2019](https://www.beigene.com.au/wp-content/uploads/2022/04/2019-scaled-1-300x142.jpg)
2020
Received first approvals for BRUKINSA® in China; received additional approvals in China for tislelizumab; secured national reimbursement in China for tislelizumab, BRUKINSA®, and an in-licensed medicine; established additional R&D center in Shanghai
2021
![2021](https://www.beigene.com.au/wp-content/uploads/2022/04/2021-300x300.jpg)
2021
Entered global strategic collaborations with Novartis for tislelizumab and ociperlimab; received approvals in the U.S. for additional indications of BRUKINSA®’s; received first approval in the EU and UK for BRUKINSA®; acquired a 42-acre site near Princeton, N.J. for a biologics manufacturing plant and clinical R&D center; completed third stock exchange listing, on the STAR Market of the Shanghai Stock Exchange